Skip Navigation

Your Environment. Your Health.

Stephen S. Ferguson, Ph.D.

Molecular Toxicology and Informatics Group

Stephen Ferguson, Ph.D.
Stephen S. Ferguson, Ph.D.
Chemist
Tel (919) 541-3799
Fax (919) 541-4255
stephen.ferguson@nih.gov
P.O. Box 12233
Mail Drop K2-02
Research Triangle Park, North Carolina 27709
Delivery Instructions

Stephen S. Ferguson, Ph.D., is a chemist in the Molecular Toxicology and Informatics Group within the Biomolecular Screening Branch of the National Toxicology Program (NTP) Division.  His primary role is to lead the development of more predictive in vitro assay approaches (e.g., in vitro liver models competent for xenobiotic metabolism in high throughput screening assays) that support identification of hazardous chemicals and exploration of mechanisms of toxicity (e.g. receptor activation).   With a background in drug metabolism pathways, drug-drug interaction mechanisms (e.g., induction of clearance pathways), and various in vitro assay systems, Ferguson supports the identification of in vitro approaches that diversify the ‘biological space’ for genomics platforms and provide more physiologically-relevant model systems for in vitro toxicology research.  Ferguson also has an interest in understanding the quantitative relationships between in vitro responses (e.g., AC50) at the cellular and molecular level and translating these data to in vivo outcomes and environmental exposure levels.  

 

Before joining the Biomolecular Screening Branch, Ferguson led the ADME/Tox research program at Life Technologies (formerly CellzDirect) where his group investigated and developed in vitro tools for hepatic biology, drug clearance, and drug-drug interaction pathway research.  Ferguson also has a background in contract research management serving for multiple years as a Study Director on numerous non-clinical pharmaceutical research studies.

 

Ferguson received a B.S. in chemistry from North Carolina State University and a Ph.D. in chemistry (bioinorganic chemistry with a minor in biotechnology) from North Carolina State University.

 

Selected Publications

  1. Wetmore BA, Wambaugh JF, Ferguson SS, Li L, Clewell HJ 3rd, Judson RS, Freeman K, Bao W, Sochaski MA, Chu TM, Black MB, Healy E, Allen B, Andersen ME, Wolfinger RD, Thomas RS.  2013.  Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays.  Toxicol Sci. 132(2):327-346.[Abstract ]
  2. Wang D, Li L, Yang H, Ferguson SS, Baer MR, Gartenhaus RB, Wang H. 2013. The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies. Blood. 121(2):329-38.[Abstract ]
  3. Lynch C, Pan Y, Li L, Ferguson SS, Xia M, Swaan PW, Wang H. 2013. Identification of novel activators of constitutive androstane receptor from FDA-approved drugs by integrated computational and biological approaches. Pharm Res. 30(2):489-501.[Abstract ]
  4. Smith CM, Nolan CK, Edwards MA, Hatfield JB, Stewart TW, Ferguson SS, Lecluyse EL, Sahi J. J. 2012. A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes. Pharm Sci. 101(10):3989-4002.[Abstract ]
  5. Zhang SY, Surapureddi S, Coulter S, Ferguson SS, Goldstein JA. 2012. Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol Pharmacol. 2012 Jun 20 82(3):529-40.[Abstract ]
  6. Black MB, Budinsky RA, Dombkowski A, Cukovic D, LeCluyse EL, Ferguson SS, Thomas RS, Rowlands JC. 2012.Cross-species comparisons of transcriptomic alterations in human and rat primary hepatocytes exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci. 127(1):199-215.[Abstract ]
  7. Wetmore BA, Wambaugh JF, Ferguson SS, Sochaski MA, Rotroff DM, Freeman K, Clewell HJ 3rd, Dix DJ, Andersen ME, Houck KA, Allen B, Judson RS, Singh R, Kavlock RJ, Richard AM, Thomas RS. 2012. Integration of dosimetry, exposure and high-throughput screening data in chemical toxicity assessment. Toxicol Sci. 125(1):157-74.[Abstract ]
  8. Wang D, Li L, Fuhrman J, Ferguson S, Wang H. 2011.The role of constitutive androstane receptor in oxazaphosphorine-mediated induction of drug-metabolizing enzymes in human hepatocytes. Pharm Res. 28(8):2034-44.[Abstract ]
  9. Rana R, Surapureddi S, Kam W, Ferguson S, Goldstein JA. 2011. Med25 is required for RNA polymerase II recruitment to specific promoters, thus regulating xenobiotic and lipid metabolism in human liver. Mol Cell Biol. 31(3):466-81.[Abstract ]
  10. Martinez SM, Bradford BU, Soldatow VY, Kosyk O, Sandot A, Witek R, Kaiser R, Stewart T, Amaral K, Freeman K, Black C, LeCluyse EL, Ferguson SS, Rusyn I. 2010. Evaluation of an in vitro toxicogenetic mouse model for hepatotoxicity. Toxicol Appl Pharmacol. 249(3):208-216.[Abstract ]
  11. Li Y, Zhou D, Ferguson SS, Dorff P, Simpson TR, Grimm SW. 2010. In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies. Xenobiotica. 40(11):721-9.[Abstract ]
  12. Li L, Hassan HE, Tolson AH, Ferguson SS, Eddington ND, Wang H. 2010. Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and hepG2 cells. J Pharmacol Exp Ther. 335(3):562-571.[Abstract ]
  13. Budinsky RA, LeCluyse EL, Ferguson SS, Rowlands JC, Simon T. 2010. Human and rat primary hepatocyte CYP1A1 and 1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran. Toxicol Sci. 118(1):224-235.[Abstract ]
  14. Rotroff DM,  Beam AL, Dix DJ, , Farmer A, Freeman KM,  Houck KA, Judson RS, LeCluyseEL, Martin MT, Reif DM, Ferguson SS. 2010. Xenobiotic metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals.  J. Toxicol.Env. Health B Crit Rev. 13(2-4):329-346.[Abstract ]
  15. Li, H, Ferguson, S.S., Wang, H. 2010. Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation. 2010. Mol Pharmacol. 78(4):704-713.[Abstract ]  
  16. Rotroff DM, Wetmore BA, Dix DJ, Ferguson SS, Clewell HJ, Houck KA, Lecluyse EL, Andersen ME, Judson RS, Smith CM, Sochaski MA, Kavlock RJ, Boellmann F, Martin MT, Reif DM, Wambaugh JF, Thomas RS. 2010. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci. 117(2):348-358.[Abstract ]

Back to Top